Core Points - The company has received notification from its controlling shareholder, Hainan Hansen Holdings, regarding the release of part of its pledged shares [1] - A total of 13,000,000 shares, accounting for 6.13% of the total share capital, were released from pledge on August 25, 2025 [1] - As of the announcement date, the controlling shareholder has pledged a total of 212,006,189 shares, which is 42.13% of its holdings [1] Summary by Sections 1. Release of Pledged Shares - Hainan Hansen released 13,000,000 shares from pledge, which represents 6.13% of its total holdings and 2.58% of the company's total share capital [1] - The shares were originally pledged on March 29, 2023, and the release date was August 25, 2025 [1] 2. Pledged Shares Situation - The total number of pledged shares by the controlling shareholder is 212,006,189, which constitutes 42.13% of its holdings [1] - The pledged shares represent 34,500,000 shares, accounting for 16.27% of the total share capital [1] 3. Other Situations - There is no risk of forced liquidation of the pledged shares, and it will not lead to a change in the company's actual control [1] - The company will continue to monitor the situation regarding the pledged shares and fulfill its information disclosure obligations as required [1]

证券日报网讯 8月26日晚间，汉森制药发布公告称，控股股东海南汉森控股（有限合伙）在长沙银行股 份有限公司华龙支行办理了股票解除质押业务，解除质押股份数量为1300万股，占其所持股份比例 6.13%，占公司总股本比例2.58%。 （编辑 楚丽君） ...

Core Viewpoint - Hansen Pharmaceutical announced that its controlling shareholder, Hainan Hansen, released 13 million shares from pledge on August 25, 2025, which accounts for 6.13% of its holdings and 2.58% of the company's total share capital [1] Summary by Relevant Categories Share Pledge Information - As of the announcement date, Hainan Hansen has a total of 34.5 million shares pledged, representing 16.27% of its holdings and 6.86% of the company's total share capital [1]

证券代码：002412 证券简称：汉森制药 公告编号：2025-018 湖南汉森制药股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 | 股东 名称 | 是 否 为 控 股 | 本次解除质 押股份数量 （股） | 占其所 持股份 比例 (%) | 占公司 总股本 比例 (%) | | 起始日 | | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 股 东 | | | | | | | | | | 海南 汉森 | 是 | 13,000,000 | 6.13 | 2.58 | 2023 29 | 年 月 3 日 | 2025 25 | 年 月 8 日 | 长沙银行 股份有限 公司华龙 支行 | | 合计 | - | 13,000,000 | 6.13 | 2.58 | | - | | - | - | 一、本次解除质押的基本情况 二、控股股东股份累计质押的情况 截至公告披露日，上述股东所持股份质押情况如下： - 1 - | | | | | | | ...

Core Points - The company, Hunan Hansen Pharmaceutical Co., Ltd., held its sixth board meeting on August 22, 2025, where it approved the 2025 semi-annual report and the appointment of a new securities affairs representative [10][11][14]. Group 1: Company Overview - Hunan Hansen Pharmaceutical Co., Ltd. is committed to ensuring the authenticity, accuracy, and completeness of its information disclosure [8]. - The company has not changed its controlling shareholder or actual controller during the reporting period [4][5]. Group 2: Financial and Operational Highlights - The company plans not to distribute cash dividends, issue bonus shares, or increase capital from reserves [2]. - The semi-annual report and its summary were published on designated information disclosure platforms [11]. Group 3: Management Changes - The board appointed Ms. Tang Lifeng as the securities affairs representative, effective from the date of the board's approval until the end of the current board's term [14]. - Ms. Tang holds a bachelor's degree in financial management and has been with the company since October 2024 [9].

Core Viewpoint - Hansen Pharmaceutical announced the appointment of Ms. Tang Lifeng as the company's securities affairs representative [2] Company Summary - The company has made a strategic decision to enhance its investor relations by appointing a new representative [2]

Group 1 - The core viewpoint of the news is that Hansen Pharmaceutical (002412) has shown a slight increase in stock price, but the company is facing a significant decline in net profit despite a modest revenue growth [1][3] - As of August 25, 2025, Hansen Pharmaceutical's stock closed at 6.97 yuan, up 1.9%, with a turnover rate of 3.81% and a trading volume of 189,800 hands, amounting to a transaction value of 1.32 billion yuan [1] - The latest financial results for Hansen Pharmaceutical indicate total revenue of 509 million yuan, a year-on-year increase of 5.91%, while net profit attributable to shareholders decreased by 31.80% to 68.54 million yuan [1] Group 2 - The company has a current ratio of 4.156, a quick ratio of 3.454, and a debt-to-asset ratio of 12.41%, indicating strong liquidity and low leverage [1] - Hansen Pharmaceutical has made investments in 7 companies and participated in 5,000 bidding projects, showcasing its active engagement in the market [2] - The company holds 42 trademark registrations and 31 patents, along with 304 administrative licenses, reflecting its commitment to intellectual property and regulatory compliance [2]

格隆汇8月25日丨汉森制药(002412.SZ)公布2025年半年度报告，上半年公司实现营业收入5.09亿元，同 比增长5.91%；归属于上市公司股东的净利润6853.84万元，同比下降31.80%；归属于上市公司股东的扣 除非经常性损益的净利润6476.95万元，同比下降31.72%；基本每股收益0.1362元。 ...

Group 1 - The core point of the article is that Hansen Pharmaceutical announced the convening of its sixth board meeting to discuss the appointment of a securities representative and reported its revenue structure for the first half of 2025, with a significant focus on the pharmaceutical industry [1][1][1] Group 2 - For the first half of 2025, Hansen Pharmaceutical's revenue composition shows that the pharmaceutical industry accounts for 99.95% of its total revenue, while other businesses contribute only 0.05% [1][1][1] - As of the report, Hansen Pharmaceutical has a market capitalization of 3.5 billion yuan [1][1][1]

Core Viewpoint - Hansen Pharmaceutical (002412.SZ) reported a revenue of 509 million yuan for the first half of 2025, reflecting a year-on-year growth of 5.91% [1] - The net profit attributable to shareholders decreased by 31.80% to 68.54 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses also fell by 31.72% to 64.77 million yuan [1] - Basic earnings per share stood at 0.1362 yuan [1] Financial Performance - Revenue for the first half of 2025: 509 million yuan, up 5.91% year-on-year [1] - Net profit attributable to shareholders: 68.54 million yuan, down 31.80% year-on-year [1] - Net profit after deducting non-recurring items: 64.77 million yuan, down 31.72% year-on-year [1] - Basic earnings per share: 0.1362 yuan [1]